Literature DB >> 25125625

Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.

Ellen Flatley1, Andy I Chen2, Xiangrong Zhao3, Elaine S Jaffe3, Jennifer B Dunlap1, Stefania Pittaluga3, Shahed Abdullah3, Susan B Olson4, Stephen E Spurgeon2, Guang Fan5.   

Abstract

OBJECTIVES: B-cell prolymphocytic leukemia (B-PLL) remains a controversial entity, and its molecular pathogenesis is largely unknown. Patients are older, typically having marked lymphocytosis and splenomegaly in the absence of lymphadenopathy. It is defined as a mature B-cell leukemia with more than 55% circulating prolymphocytes. Leukemic mantle cell lymphoma and chronic lymphocytic leukemia in prolymphocytic transformation must be excluded.
METHODS: Case archives were retrospectively reviewed for B-PLL in patients without a previous diagnosis of chronic lymphocytic leukemia or other B-cell neoplasm.
RESULTS: We identified six cases of B-PLL with available cytogenetic data, five of which showed evidence of aberrations in MYC. Three cases showed additional signals for the MYC gene by fluorescence in situ hybridization (FISH), and two cases demonstrated t(8;14)MYC/IGH by karyotyping or FISH. High levels of MYC protein expression were detected in all cases tested with MYC aberrations.
CONCLUSIONS: These results suggest that deregulation of MYC plays an important role in the pathogenesis of B-PLL and expands the spectrum of B-cell neoplasms associated with aberrations of MYC. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Cytogenetics; FISH; Leukemia; MYC; Prolymphocytic leukemia

Mesh:

Substances:

Year:  2014        PMID: 25125625     DOI: 10.1309/AJCPUBHM8U7ZFLOB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation.

Authors:  Xiaofeng Shi; Rong Ba; Haiyan You; Qian Jiang; Jiansong Huang; Jianhua Mao; Lanxiu Han; Shuo Zhang; Qin Zhuang; Xianqiu Yu; Lixia Wang; Yun Wang; Dongya Li; Wei Zhu; Yong Zhang; Yan Zhu; Xiaodong Xi
Journal:  Front Med       Date:  2017-10-27       Impact factor: 4.592

Review 2.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

3.  B-cell lymphomas with discordance between pathological features and clinical behavior.

Authors:  Laurence de Leval; Christiane Copie-Bergman; Andreas Rosenwald; Lisa Rimsza; Stefania Pittaluga; Bettina Bisig; Stefan Dirnhofer; Fabio Facchetti; Stefano Pileri; Falko Fend; Andrew Wotherspoon
Journal:  Virchows Arch       Date:  2017-06-01       Impact factor: 4.064

4.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.